Sihuan Pharmaceutical Holdings Group (HKG:0460) unit's Huisheng Biopharmaceutical said China's National Medical Products Administration (NMPA) approved a new drug registration for the treatment of Type II diabetes, according to a Wednesday filing on the Hong Kong bourse.
Insulin Degludec Injection is a long-acting basal insulin.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments